Press Release

Astellas Announces Personnel Changes and Organizational Changes

Tokyo, August 24, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.

  1. Personnel Changes effective on October 1, 2017

    Name

    New Title

    Current Title

    Catherine J. Wertjes

    Head of

    Ethics & Compliance (No change: only Japanese organization name will be changed)

    Head of

    Ethics & Compliance

    Hideki Yamanaka

    Vice President, Ethics & Compliance,

    Japan and Asia Oceania

    Vice President, Ethics & Compliance, Japan and East Asia

    Emi Ito

    Vice President, Sales Capability

    Development & Training, Japan Sales & Marketing

    Senior Director, Product Marketing,

    Japan Sales & Marketing

    Tomonobu Koizumi

    Staff Executive Director, Innovation & Incubation Research Labs., DDR

    Vice President, Regenerative Medicine Labs., DDR

    Atsunori Kaibara

    Staff Executive Director, Japan-Asia Clinical Pharmacology, Development

    Senior Director, Japan-Asia Clinical Pharmacology, Development

    DDR: Drug Discovery Research

  2. Organizational Changes effective on October 1, 2017

Regenerative Medicine Labs.

To further increase the productivity for regenerative medicine research, Regenerative Medicine Labs. will be reorganized and integrated into Astellas Institute for Regenerative Research (AIRM). AIRM will be a major function of regenerative medicine research in Astellas group. Astellas continues to pursue joint research and collaborations in Japan as ever.

Sales Capability Development & Training

The human resources functions (talent management, labor administration, compensation and benefit, diversity & inclusion, etc.) at Japan Sales & Marketing will be transferred to Human Resources and this department will focus on the training function specific to Japan Sales & Marketing. In accordance with this change, "Human Resources Development" will be renamed "Sales Capability Development &

Training".

### About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc. Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Astellas Pharma Inc. published this content on 24 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 August 2017 05:07:03 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/pdf/170824_1_Eg.pdf

Public permalinkhttp://www.publicnow.com/view/FDEEDD5E617111A403D2E84EB66037176D636DAA